Frank KungManaging Partner
Vivo Capital

Dr. Kung is a founding member of Vivo Capital (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California.
Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan.
Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.

Hongbo LuManaging Partner
Vivo Capital

Hongbo Lu, Ph.D., is a Managing Partner of Vivo Capital. Dr. Lu has close to 20 years of healthcare investment and operational experience in both public securities and private companies. Prior to joining Vivo, she served as a Managing Partner at Lilly Asia Ventures (LAV). Prior to that, she served as a Managing Director at OrbiMed Advisors. Over her investment career, Dr. Lu has invested extensively in both China and the U.S. She previously served on the boards of Turning Point Therapeutics (TPTX), CrownBio (6554.TT, acquired by JSR), Avedro (AVDR, acquired by Glaukos), and Passage (PASG, observer). She was extensively involved in the company incubations of ADARx, Elpiscience, Geneception, Perfuse, Terns, and Ronovo since inception. Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and was involved in biotech start-ups in the Bay Area previously.

Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University.

James LiCo-founder, Chairman of the Board and CEO
JW Therapeutics

In early 2016, James Li co-founded JW Therapeutics with Juno Therapeutics and WuXi AppTech, serving as Chairman of the Board and Chief Executive Officer.

Prior to JW Therapeutics, James served as Vice President and the founding General Manager Greater China at Amgen, Partner at Kleiner Perkins Caufield & Byers life science practice, and several leadership positions across the US and Asia Pacific at Merck Co. & Inc.

Norman Chen Venture Partner
6 Dimensions Capital

Mr. Chen began his healthcare career at Baxter International, where he was responsible for the kidney dialysis business unit across Asia. In 1995, Mr. Chen founded Asia Renal Care, Ltd. to provide international-standard dialysis services in Asia, and led the company to become the leading independent dialysis group in Asia with over 70 centers in Taiwan, Singapore, the Philippines, Japan, Korea and Malaysia.

In 2002, Mr. Chen joined Walden International as Entrepreneur-in-Residence. In 2004, he co-founded DeltaHealth as a provider of international-quality cardiovascular care in China. DeltaHealth opened its first clinic in Shanghai in 2010 and a 200-bed cardiovascular hospital in 2016.

From 2005-2012, Mr. Chen led healthcare investing at Fidelity Growth Partners Asia (now called Eight Roads Ventures), where he was responsible for investments in several successful companies in China in the CRO, specialty pharmaceutical, medical device, medical service and other healthcare areas.

Mr. Chen is a Venture Partner at 6 Dimensions Capital, a leading US-China life sciences fund with $1 billion under management.

Mr. Chen is on the boards or advisory councils of the following non-profit organizations – Children’s Medical Foundation (HK), Marine Science Institute, and Positive Coaching Alliance.

Mr. Chen has a BS degree in Biology from the Massachusetts Institute of Technology and an MBA from Stanford University. He lives in the SF Bay Area.

Marietta WuManaging Director
Quan Capital

Dr. Marietta Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments. She is a founding member of Zai Lab and served as COO and Director of the company prior to Quan Capital. Zai Lab is a NASDAQ listed company widely recognized as a leader in bringing innovative and transformative medicines to China. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry. She was Managing Director at Burrill & Company, leading Burrill’s investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Dr. Wu is a frequent speaker and author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference. Prior to her focus on healthcare investments and company building, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.

Dr. Wu serves on the board of Crescendo Biologics, Kira Pharmaceutical and Qiagen (Suzhou) Translational Medicine Co., Ltd. She was a board member of Zai Lab Limited (NASDAQ: ZLAB), Taiwan Liposome Company (GTSM: 4152), JHL Biotech (TWEM: 6540), and General Biologics Corporation (TWEM: 4117).

Cyber Cao Managing Director
Sequoia Capital China

Prior to joining Sequoia, Cyber participated most of the investment starting from Vivo Fund VII in China and served on the board of SMC and Gengmei APP. Before that, Cyber was the leader of Nycomed North Asia strategy and business development, and He helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese pharmaceutical player. In his early career, Cyber was at McKinsey & Company where he worked with both multi-national and local pharmaceutical companies on corporate strategy. Cyber received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University.

Jon Liong Managing Director
Lychee Group

Jon is the Founder and Managing Partner of Lychee Group, a company focused on creating the highest-quality events for China's life sciences industry.
Jon brings over 15 years of success in the strategic planning, organization and marketing of pharmaceutical and biotech business-to- business conferences.
In 1999, he joined Strategic Research Institute, a leading New York- based conference company. During his tenure there he organized and directed over 100 successful life sciences conferences and managed the production of over 40 events annually. As Managing Director, Jon led the company’s global expansion into China, conceiving and launching the "IMPACT CHINA: Pharmaceutical Global R&D" series, which was the first ever Western-organized conference covering China's life sciences industry.
Since starting Lychee, Jon has helped launch some of the highest profile healthcare events in China including "China Healthcare Investment Conference (CHIC)," "ChinaTrials: Global Clinical Development Summit," and "Asia Healthcare CEO Meeting by OrbiMed." Jon received his B.S. in Marketing from the New York University Stern School of Business.

Karen Wong Partner
Wilson Sonsini Goodrich & Rosati

Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich &: Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs. Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich &: Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.
Prior to practicing law, Karen conducted doctoral and post-doctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology. Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.